Match!
Daniel D. Von Hoff
Translational Genomics Research Institute
CancerPathologyImmunologyChemotherapyMedicine
839Publications
84H-index
38kCitations
What is this?
Publications 850
Newest
#1David GoldsteinH-Index: 84
#2Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
Last. Brian LuH-Index: 7
view all 13 authors...
OBJECTIVES This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis. METHODS Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) (nab-paclitaxel plus gemcitabine vs gemcitabine) data set. Factors significantly (P < 0.1) associated with overall survival (OS) in a univariable model or with known clinical relevance were tested further. In a multivariable model, factors associated with OS (P < 0.1) were selec...
Source
#1J. Spencer Lane (University of Texas Health Science Center at Houston)
#2Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
Last. Ajay Goel (Beckman Research Institute)H-Index: 65
view all 4 authors...
Pancreatic cancer remains one of the deadliest diagnoses a patient can receive. One of the reasons for this lethality is that this malignancy is often detected very late due to a lack of symptoms during the early stages. In addition to the lack of symptoms, we currently do not have a reliable biomarker for screening. Carbohydrate antigen (CA) 19-9 has a sensitivity between 79% and 84% and a specificity of 82–90%, making it unreliable for early detection. Recently, there have been numerous studie...
Source
#1Katherine M. Bever (Johns Hopkins University)H-Index: 4
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
Last. Annie A. Wu (Johns Hopkins University)H-Index: 5
view all 21 authors...
Source
#1Bruno Bockorny (Harvard University)H-Index: 8
#2Valerya Semenisty (Rambam Health Care Campus)H-Index: 1
Last. Katrina S. Pedersen (WashU: Washington University in St. Louis)H-Index: 3
view all 26 authors...
Programmed cell death 1 (PD-1) inhibitors have limited effect in pancreatic ductal adenocarcinoma (PDAC), underscoring the need to co-target alternative pathways. CXC chemokine receptor 4 (CXCR4) blockade promotes T cell tumor infiltration and is synergistic with anti-PD-1 therapy in PDAC mouse models. We conducted a phase IIa, open-label, two-cohort study to assess the safety, efficacy and immunobiological effects of the CXCR4 antagonist BL-8040 (motixafortide) with pembrolizumab and chemothera...
3 CitationsSource
#1Erkut BorazanciH-Index: 8
#2Gayle S. JamesonH-Index: 12
Last. Ronald L. KornH-Index: 14
view all 17 authors...
Source
#1Raju KandimallaH-Index: 7
#2Tadanobu ShimuraH-Index: 11
Last. Daniel D. Von HoffH-Index: 84
view all 12 authors...
OBJECTIVE: The aim of the study was to perform mRNA-miRNA regulatory network analyses to identify a miRNA panel for molecular subtype identification and stratification of high-risk patients with pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: Recent transcriptional profiling effort in PDAC has led to the identification of molecular subtypes that associate with poor survival; however, their clinical significance for risk stratification in patients with PDAC has been challenging. METHODS: By ...
Source
#1Cameron WestH-Index: 7
#2Shawn G. Kwatra (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 11
Last. Paul Dent (VCU: Virginia Commonwealth University)H-Index: 81
view all 6 authors...
Objective: We aimed to compare the efficacy of the plant-based compound GZ17-6.02 compared to 5-fluorouracil to assess its potential as a novel therapy against actinic keratosis (AK).Materials and ...
Source
#1Ramesh K. Ramanathan (TGen: Translational Genomics Research Institute)H-Index: 43
#2Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
Last. C. Pena (Bayer AG: Bayer HealthCare Pharmaceuticals)H-Index: 9
view all 11 authors...
BACKGROUND: Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy. OBJECTIVE: This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose, pharmacokinetics, tumor response, fluorodeoxyglucose positron emission tomography (FDG-PET) pharmacodynamics, and biomarker explorations for the combination of pan-PI3K inhibitor copanlisib and allosteric MEK inhibitor refametinib in patients with advanced solid tumors. PATIENTS AND ...
Source
#1Yanghee Woo (Beckman Research Institute)H-Index: 8
#2Zhifang Zhang (City of Hope National Medical Center)
Last. Yuman Fong (Beckman Research Institute)H-Index: 109
view all 10 authors...
Abstract Background Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC) is fatal. Our preclinical study presents an effective treatment against PDAC PC employing a novel oncolytic viral agent, CF33-hNIS-antiPDL1. Study Design CF33-hNIS-antiPDL1 is a genetically engineered chimeric orthopoxvirus, CF33, armed with the human Sodium Iodide Symporter (hNIS) and anti-PD-L1 antibody (anti-PD-L1). The in vitro cytotoxic ability of this virus against five PDAC cell lines was teste...
Source
Abstract Cis-diamminedichloroplatinum (II) (DDP) leads the series of platinum coordination complexes, a new class of cytotoxic agents. The antitumor and toxic effects of this drug are discussed. It...
12345678910